Reversible	reversible	O	O	O	O
dilated	dilated	O	DISEASE	OTHERS	I
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
related	related	O	O	O	O
to	to	O	O	O	O
amphotericin	amphotericin	CHEMICALS	O	OTHERS	I
B	b	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
describe	describe	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
dilated	dilated	O	DISEASE	OTHERS	I
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
and	and	O	O	O	O
clinical	clinical	O	O	O	O
congestive	congestive	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
after	after	O	O	O	O
2	2	O	O	O	O
months	months	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
amphotericin	amphotericin	CHEMICALS	O	OTHERS	I
B	b	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
AmB	amb	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
for	for	O	O	O	O
disseminated	disseminated	O	O	O	O
coccidioidomycosis	coccidioidomycosis	O	O	OTHERS	I
.	.	O	O	O	O

His	his	O	O	O	O
echocardiographic	echocardiographic	O	O	O	O
abnormalities	abnormalities	O	O	O	O
and	and	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
resolved	resolved	O	O	O	O
after	after	O	O	O	O
posaconazole	posaconazole	O	O	OTHERS	I
was	was	O	O	O	O
substituted	substituted	O	O	O	O
for	for	O	O	O	O
AmB.	amb.	O	O	O	O
It	it	O	O	O	O
is	is	O	O	O	O
important	important	O	O	O	O
to	to	O	O	O	O
recognize	recognize	O	O	O	O
the	the	O	O	O	O
rare	rare	O	O	O	O
and	and	O	O	O	O
potentially	potentially	O	O	O	O
reversible	reversible	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
AmB.	amb.	O	O	O	O

